Nasdaq Capital Market vs. NYSE American?
A Dual Listing Guide for Small TASE Companies
The Nasdaq Capital Market and NYSE American represent the two premier U.S. exchanges for emerging growth companies, particularly appealing to smaller TASE-listed partnerships or companies seeking dual listings to tap global liquidity and institutional capital.
The Markets in general…
Nasdaq operates 3 equities markets in the USA that are dependent on certain financial, liquidity and corporate governance requirements. They are the NASDAQ Global Select, Global and Capital Markets. Most smaller issuers prefer the Capital Market because it provides the most flexibility for their offerings. Regardless, all Nasdaq markets are fully electronic and growth-oriented, offers flexible point-in-time listing standards—like $5 million in stockholders’ equity or $50 million market value of listed securities, paired with a $15 million public float—making it more accessible for sub-$27 million (100M NIS) Israeli firms via quick raises or PIPEs, without stringent pre-listing seasoning periods.
In contrast, NYSE American, blending auction-style trading with a reputation for stability, has tightened its 2026 rules to demand sustained metrics (e.g., 90 consecutive days at $4 share price and $50-75 million market cap under key standards) and slightly higher floats (up to $20 million), positioning it as a prestige play better suited to steadier earners at the upper end of the small-cap spectrum.
For a TASE-listed limited partnership/corporation with under 100 million NIS market cap (roughly $27 million at current rates), pursuing a U.S. dual listing can unlock deeper liquidity, institutional capital, and global visibility. Nasdaq Capital Market and NYSE American stand out as the most accessible U.S. venues for such micro-to-small caps. Both tightened standards in 2026, converging on $4 minimum bid prices and $15 million public floats, but key differences in flexibility, seasoning periods, and prestige remain.morganlewis+2
This post compares the two for TASE issuers, focusing on quantitative hurdles, costs, practical paths, and strategic fit for your already listed company.
Core Listing Standards Side-by-Side
For TASE issuers under 100M NIS, Nasdaq’s speed and lower barriers often win out, though both unlock U.S. visibility at comparable upfront costs of $500K-900K, here’s why:
Both exchanges offer alternative standards (equity, market value, net income), but NYSE American now demands more "seasoning"—sustained metrics over 90 days—while Nasdaq emphasizes point-in-time snapshots with some flexibility for emerging firms.
| Requirement | Nasdaq Capital Market | NYSE American (2026 Updates) |
|---|---|---|
| Stockholders' Equity | ≥ $5M (Equity Std); $4M (others) | ≥ $4M (most standards) |
| Net Income | ≥ $750K (1 recent yr or 2/3 yrs) | Similar earnings tests; float ≥ $15M |
| Market Cap | $50M listed securities | $50M (Std 3); $75M (Std 4) |
| Public Float Value | ≥ $15M unrestricted | $15M (Stds 1–3); $20M (Std 4) |
| Public Holders | ≥ 300 round-lot (100+ shares) | ≥ 300–400; unrestricted focus |
| Share Price | ≥ $4.00 bid at listing | ≥ $4.00 uniform |
| Seasoning | Limited; mostly at listing time | Required for cap/price in Stds 3–4 |
For a <$27M TASE firm, Nasdaq's Equity or Net Income standards are often reachable via a small PIPE or rights offering to hit $15M float. NYSE American's higher caps (up to $75M) and 90-day hold make it tougher without prior U.S. momentum.
No explicit working capital or revenue minimums apply to either, but Nasdaq/NYSE review overall viability of the business. Revenues matter indirectly via net income paths.
Accessibility for Sub-100M NIS TASE Listings
TASE partnerships ($27M cap max) often trade thinly, complicating Nasdaq/NYSE floats. Nasdaq Capital Market edges ahead for TASE crossovers: no special dual-listing waiver exists, but its $50M market-value test aligns better with small TASE caps after a modest raise.
NYSE American's 2026 tweaks closed its "flexibility gap," banning resale-restricted shares in float calcs and mandating 90-day price/cap stability. A TASE name at NIS 80M ($21M) might need 2-3x growth or dilution to hit NYSE's $50M+ reliably over 90 days—harder amid TASE volatility.
Nasdaq suits "fast-track" dual listings: qualify under Equity Std with $5M equity (common for profitable TASE firms) and $15M float via existing free-float plus a $5-10M placement.
Costs: Upfront and Ongoing
Expect $300K-800K total for either, scaling with complexity. No major spread between venues, but Nasdaq's fee tiering favors smaller caps.bassberrysecuritieslawexchange+1
Exchange Fees (Nasdaq): $50-75K initial; $45-70K annual. NYSE American: Similar initial ($50-100K); annual up to $70K.
Legal/Audit: $200-500K (See SEC Form F-1/20-F, PCAOB audit bridge from Israeli GAAP).
Underwriter/Advisor: 6-8% of any raise (e.g., $300K on $5M PIPE); flat $100-200K if pure listing.
Ongoing: $250K+/yr (SEC reporting, IR). Nasdaq often cheaper long-term (max $200K annual vs. NYSE tiers).
For TASE firms, Israeli counsel adds $50-100K to harmonize disclosures for the initial listing. Fortunately, Nasdaq's electronic model trims some IR costs vs. NYSE's hybrid prestige push (more about this in a minute).
Prestige, Liquidity, and Investor Base
Nasdaq Capital Market signals "growth/tech," drawing VCs and retail for Israeli biotechs/partnerships. Trading volumes run higher (fully electronic), aiding small caps.
NYSE American evokes stability but skews toward U.S. regionals/SMEs; less "Israel premium" than Nasdaq, where peers like TASE-Nasdaq duals (e.g., historical tech crossovers) cluster. Post-2026, NYSE's tighter liquidity rules may boost perceived quality but squeeze micro-caps.hawkinsight+1
For companies with less than 100M NIS of market cap, the Nasdaq often yields faster liquidity ramps; NYSE suits if targeting institutions valuing its brand.
Strategic Roadmap for TASE Issuers
Here’s where to start the journey of your dual-listing program.
Audit Gap: Bridge to PCAOB via Israeli firm sign-off (3-6 months, $100K). There are many mid-tier US accounting firms that can work with your Israeli Auditor and a fraction of the cost of a big 4 firm
Float Build: Target $15M unrestricted via TASE block sale/PIPE (aim 1.1M+ public units). Ideally, this capital comes from a mix of Israeli and US inventors and if you work with your advisor and lead bookrunner, they will help you achieve this.
Price Tune: Stabilize at $4+ (Nasdaq easier sans 90-day rule). In order to be effective at this, you need two or three market makers in place before the listing starts, otherwise most listings suffer dramatically on both exchanges during the first few months.
Build Investor Messaging: Often, US investors have never heard of your company's amazing offerings. You need to engage an investor advisory team that will provide messaging and introductions to public company investors that might be interested in your new listing at least 60 days before the target listing date. These introductions can be related to the PIPE deal or even non-deal in nature, because both types build your brand within the investor community and create added visibility and trading liquidity.
File/Launch: Either application will take between 4 to 6 months, so it’s important to engage U.S./IL counsel early. Fortunately there are many US attorneys doing great work and charging Israeli fees (vs. NYC fees).
Bottom Line
So which one is right for you?
Nasdaq Wins for Speed& Flexibility: Ideal for 50-100M NIS TASE companies eyeing quick U.S. access without massive dilution.
NYSE American for Prestige: Viable at upper end ($25M+) if 90-day seasoning feasible; better for steady earners and more established companies.
We believe that sub-100M NIS TASE listings should prioritize Nasdaq Capital Market. It has lower effective bars, no harsh seasoning, tech-friendly vibe, and cost parity.
NYSE American's new 2026 rigor makes it a stretch unless you're already $40M+ with stable trading and consistent revenues.
As always, though, you should consult a licensed FINRA advisor and US securities counsel because the rules are evolving, and a hybrid PIPE + listing often closes gaps.
Regardless which market you choose, a dual-listing elevates TASE names and opens your company up to capital sources it otherwise would be unable to reach.
